Rocaglamide

• UNSPSC Description:

  Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC50 of ~50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia[1][2][3].

• Target Antigen:

  Eukaryotic Initiation Factor (eIF); HSP; NF-κB

• Type:

  Natural Products

• Related Pathways:

  Cell Cycle/DNA Damage;Metabolic Enzyme/Protease;NF-κB

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Rocaglamide.html

• Purity:

  99.34

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O[C@]12[C@](OC3=CC(OC)=CC(OC)=C32)(C4=CC=C(C=C4)OC)[C@H](C5=CC=CC=C5)[C@H]([C@H]1O)C(N(C)C)=O

• Molecular Weight:

  505.56

• References & Citations:

  [1]Santagata S, et al. Tight coordination of protein translation and heat shock factor 1 activation supports the anabolic malignant state. Science. 2013 Jul 19; 341(6143): 1238303.|[2]Luan Z, et al. Rocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation. Mol Med Rep|[3]Baumann B, et al. Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T-cells. J Biol Chem. 2002 Nov 22;277(47):44791-800.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  84573-16-0